Clinical Trial For Concussion Therapeutic

Dr. Michael Wyand is a biopharmaceutical executive with over 25yrs experience in managing and building successful product and service-oriented life science companies. He is the CEO and Director of Oxeia Biopharmaceuticals, a clinical-stage biotech company developing new, innovative therapeutics for mild traumatic brain injury (mTBI), known as concussion, and related neuro-metabolic dysfunction. Oxeia is actively recruiting participants for its ongoing Phase 2 clinical trial of OXE103 at the University of Kansas Medical Center. OXE103 could advance treatment directly addressing the underlying pathology of mTBI. An accomplished leader, Dr. Wyand has substantial experience managing R&D and as a corporate officer. He trained in comparative pathology at Harvard Medical School, received his DVM from Purdue University and his PhD in Pathology from the University of Connecticut. He received a BS in Biology from the University of Connecticut where he graduated with honors as a University Scholar. In second hour, Rico Petrini #49, an All-Conference Linebacker and Team MVP at Oregon State University, shares how he went from near perfect health to extreme behavioral, neurological, and physical changes this past year at 49 years old and the clinical trial using Photobiomodulation that might have saved him.